CLINICAL STUDIES
Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina
David J. Webb, MD*,
Gary J. Muirhead, BSc ,
Maria Wulff, BSc,
J. Andrew Sutton, MD ,
Roberto Levi, MD and
Wallace W. Dinsmore, MD||
* Department of Medicine, The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
Pfizer Central Research, Sandwich, Kent, United Kingdom
Guildford Clinical Pharmacology Unit, Royal Surrey County Hospital, Guildford, United Kingdom
Department of Pharmacology, Cornell University, Weill Medical College, New York, New York, USA
|| Department of Genitourinary Medicine, The Royal Victoria Hospital, Belfast, United Kingdom
Manuscript received June 29, 1999;
revised manuscript received January 18, 2000,
accepted March 24, 2000.
Reprint requests and correspondence: David J. Webb, University Department of Medical Sciences, The University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
D.J.Webb{at}ed.ac.uk
OBJECTIVE
We sought to study the effects of a single oral dose of sildenafil citrate (50 mg) on blood pressure (BP) in men taking the nitric oxide (NO) donor drugs isosorbide mononitrate (ISMN) or glyceryl trinitrate (GTN) for stable angina.
BACKGROUND
Sildenafil, a selective phosphodiesterase type 5 inhibitor, is an orally effective treatment for erectile dysfunction. The presence of phosphodiesterases in the vasculature suggests the possibility of an interaction between sildenafil and NO donor drugs.
METHODS
Two double-blind, placebo-controlled, randomized, two-way crossover trials were undertaken. Sixteen male patients received oral ISMN (20 mg twice a day) for five to seven days before their dose of sildenafil or placebo and continued receiving ISMN daily until administration of the alternate drug seven days later. For the second study, 15 male patients received sublingual GTN (500 µg) 1 h after sildenafil or placebo on each of two study days, which were seven days apart. Sitting or standing BP was measured before and for 6 h after the administration of the study drug.
RESULTS
The effects of sildenafil plus ISMN on BP (standing mean maximum reductions from baseline in systolic/diastolic BP, –52/–29 mm Hg) were greater than the effects of placebo plus ISMN on BP (–25/–15 mm Hg; p < 0.001). Sildenafil plus GTN also resulted in greater sitting mean maximum reductions from baseline in systolic/diastolic BP (–36/–21 mm Hg) compared with placebo plus GTN (–26/–12 mm Hg; p < 0.01).
CONCLUSIONS
Coadministration of sildenafil with ISMN or GTN produced significantly greater reductions in BP than ISMN or GTN alone. Based on these data, sildenafil should not be administered to patients taking nitrates.
|
Abbreviations and Acronyms
| | AUEC | = area under the effect curve | | BP | = blood pressure | | cGMP | = cyclic guanosine monophosphate | | ED | = erectile dysfunction | | GTN | = glyceryl trinitrate | | HR | = heart rate | | ISMN | = isosorbide mononitrate | | NO | = nitric oxide | | PDE5 | = phosphodiesterase type 5 |
|
This article has been cited by other articles:
|
|
|
|
 
J. W. M. Cheng and S. R. Berhane
Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors
American Journal of Lifestyle Medicine,
May 1, 2009;
3(3):
201 - 211.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
e1 - e90.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Circulation,
April 14, 2009;
119(14):
e391 - e479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Eur. Respir. J.,
July 1, 2008;
32(1):
198 - 209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Oliver, V. P. Melville, and D. J. Webb
Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension
Hypertension,
October 1, 2006;
48(4):
622 - 627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Teixeira, F. B. M. Priviero, and R. C. Webb
Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta
J. Pharmacol. Exp. Ther.,
February 1, 2006;
316(2):
654 - 661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S D Robinson, C A Ludlam, N A Boon, and D E Newby
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease
Heart,
February 1, 2006;
92(2):
170 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mahler and I. Baumgartner
More Potential for Sildenafil Than Potency
Circulation,
November 8, 2005;
112(19):
2894 - 2895.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gupta, A. Kovar, and B. Meibohm
The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction
J. Clin. Pharmacol.,
September 1, 2005;
45(9):
987 - 1003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kekilli, Y. Beyazit, T. Purnak, S. Dogan, and E. Atalar
Acute Myocardial Infarction After Sildenafil Citrate Ingestion
Ann. Pharmacother.,
July 1, 2005;
39(7):
1362 - 1364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M Setter, J. L Iltz, J. E Fincham, R K. Campbell, and D. E Baker
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Ann. Pharmacother.,
July 1, 2005;
39(7):
1286 - 1295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner
Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction
Circulation,
November 9, 2004;
110(19):
3149 - 3155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Schwinn, D. T. Price, and P. Narayan
{alpha}1-Adrenoceptor Subtype Selectivity and Lower Urinary Tract Symptoms
Mayo Clin. Proc.,
November 1, 2004;
79(11):
1423 - 1434.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner, A. M. Hutter, J. T. Emmick, M. I. Mitchell, J. Denne, and G. Jackson
Reply
J. Am. Coll. Cardiol.,
June 2, 2004;
43(11):
2150 - 2151.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. DeBusk
Sexual Activity in Patients With Angina
JAMA,
December 17, 2003;
290(23):
3129 - 3132.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner, A. M. Hutter, J. T. Emmick, M. I. Mitchell, J. Denne, and G. Jackson
Time course of the interaction between tadalafil and nitrates
J. Am. Coll. Cardiol.,
November 19, 2003;
42(10):
1855 - 1860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.T. Emmick, S.R. Stuewe, and M. Mitchell
Overview of the cardiovascular effects of tadalafil
Eur. Heart J. Suppl.,
December 1, 2002;
4(suppl_H):
H32 - H47.
[Abstract]
[PDF]
|
|
|
|
|
|
|
U. Ikeda, Y. Maeda, K. Yamamoto, and K. Shimada
C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes
Cardiovasc Res,
October 1, 2002;
56(1):
86 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jackson
Cardiovascular safety in erectile dysfunction treatment
The British Journal of Diabetes & Vascular Disease,
July 1, 2002;
2(4):
301 - 304.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Y. Yoo, H. S. Kim, J.-D. Moon, and J. Lee
Sildenafil (Viagra(R)) Augments Sodium Nitroprusside-Induced But Not Nitroglycerin-Induced Hypotension in Dogs
Anesth. Analg.,
June 1, 2002;
94(6):
1505 - 1509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Arruda-Olson, D. W. Mahoney, A. Nehra, M. Leckel, and P. A. Pellikka
Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery Disease: A Randomized Crossover Trial
JAMA,
February 13, 2002;
287(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Ignarro, C. Napoli, and J. Loscalzo
Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide: An Overview
Circ. Res.,
January 11, 2002;
90(1):
21 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Parker and T. Gori
Tolerance to the Organic Nitrates: New Ideas, New Mechanisms, Continued Mystery
Circulation,
November 6, 2001;
104(19):
2263 - 2265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Swissa, T. Ohara, M.-H. Lee, S. Kaul, P. K. Shah, H. Hayashi, P.-S. Chen, and H. S. Karagueuzian
Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle
Am J Physiol Heart Circ Physiol,
May 1, 2002;
282(5):
H1787 - H1792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
